Home > Healthcare & Medical Devices > Urinalysis Market
Industry Overview
Urinalysis Market was valued at more than USD 3.4 billion in 2021 and is anticipated to progress at a 5.6% CAGR through 2028 owing to the increasing pregnancy rate across the developed and developing nations. Rising incidence of chronic diseases owing to the lifestyle changes coupled with growing awareness regarding routine medical check-ups in developed countries will augment the industry growth in the forthcoming years.
Get more details on this report - Request Free Sample PDF
Need to ensure safety and health of women during pregnancy will drive the testing volume. Moreover, changes in hormone levels during pregnancy increases the risk of urinary tract infection in women that has a higher chances of kidney damage. Further, UTIs can cause serious pregnancy complications such as premature birth, high blood pressure, low birth weight and severe preeclampsia. Therefore, preference and recommendations from healthcare professionals for urine testing during pregnancy will boost the urinalysis market growth during the forthcoming years.
| Report Coverage | Details |
|---|---|
| Base Year: | 2021 |
| Market Size in 2021: | USD 3.5 Billion |
| Forecast Period: | 2022 to 2028 |
| Forecast Period 2022 to 2028 CAGR: | 5.6% |
| 2028 Value Projection: | USD 5.3 Billion |
| Historical Data for: | 2017 to 2021 |
| No. of Pages: | 170 |
| Tables, Charts & Figures: | 299 |
| Segments covered: | Product, Application, End-use and Region |
| Growth Drivers: |
|
| Pitfalls & Challenges: |
|
Get more details on this report - Request Free Sample PDF
The urinalysis industry continued to witness significant revenue growth during the COVID-19 pandemic. The high risk of COVID-19 infection among patients with existing history of chronic kidney disease (CKD) led to increased demand for routine urinalysis during the period. Availability of home testing products allowed such patients to effectively manage disease diagnosis at home without visiting physician offices.
Further, as per the data by the European Kidney Health Alliance, nearly 58% of hospitalized COVID-19 patients were affected by Acute Kidney Injury (AKI) with an associated mortality rate of more than 30%. Thus, the increased risk of CKD among COVID-19 patients has also stimulated the demand for urinalysis in healthcare settings and contributed to the urinalysis market share.
Urinalysis is also known as urine test that uses a urine sample to examine visual, chemical and microscopic aspects of urine to assess patient health. Urinalysis tests are commonly used by healthcare providers to check or monitor specific health disorders, damage to the kidney as well as to diagnose urinary tract infections.
High risk of CKDs among geriatric population suffering through chronic conditions will impel the market statistics
The growing geriatric population in developed and developing countries is anticipated to boost the market demand. The increasing prevalence of diabetes, liver, and renal diseases with aging will significantly contribute to the demand for urine tests in diagnosis. Incidence of such chronic conditions among elderly population lead to higher frequency of prescriptions for tests like creatinine, albumin, glucose, ketones, and bilirubin among others.
According to the World Health Organization, the number of people aged 60 years and over is estimated to increase from 1 billion in 2020 to 1.4 billion by 2030. With increasing base of this age group, the industry is estimated to foresee tremendous growth. Additionally, higher risk of chronic kidney conditions with structural and functional changes in organs with aging will favour the testing volume.
Product developments allowing automation in urinalysis will offer unprecedented growth opportunities
Get more details on this report - Request Free Sample PDF
Based on product, the urinalysis market is segmented into consumables and instruments. Consumables are further bifurcated into reagents, dipsticks, and disposables. Instruments is subclassified into biochemical urine analyzer and automated urine sediment analyzers. The urinalysis instruments market was valued at over USD 1,000 million revenue in 2021 and is expected to foresee significant growth from 2022 to 2028 due to the increasing preference by healthcare professionals for automated urine analyzers.
Product developments have improved the automation process in urinalysis allowing accurate test results in case of complicated and serious illness. Additionally, infrastructure development in facilities leading to increasing adoption such advanced instruments will strengthen the segment growth potential in the coming years.
Increasing risk of urinary tract infections (UTI) in women will strengthen the market outlook
Based on application, the urinalysis market is segmented into urinary tract infection, kidney diseases, pregnancy, diabetes, and others. The urinary tract infections (UTI) segment is anticipated to progress at a 5.2% CAGR through 2028 due to increasing incidence rate of urinary tract infections in developed and developing nations.
For instance, according to the National Kidney Foundation, the UTIs lead to approximately 10 million physician visits each year in the U.S. and are highly prevalent among women. Further, the prevalence of risk factors that possess high risk of UTI will contribute to the existing disease burden. Thus, growing availability and accessibility of diagnostic products across developed regions for early disease diagnosis will positively influence the segment demand.
Accuracy in diagnostic tests and availability of specialists in clinical laboratories will foster the industry landscape
Get more details on this report - Request Free Sample PDF
The urinalysis market on basis of end-use is segmented into hospitals, clinical laboratories, home healthcare and others. The clinical laboratories segment held more than 31% revenue share in 2021 and is anticipated to witness substantial CAGR during the forecast period. As clinical laboratories offer various advantages that helps in determining a course of action or treatment for a patient, the facilities are anticipated to foresee increased volume of urinalysis that will contribute to the market expansion.
Additionally, collaboration of clinical laboratories and hospital settings for various diagnostic tests to reduce cost, time and human resources is expected to impel the urinalysis market growth. Moreover, availability of skilled administrators and specialists in settings will drive the customer preference towards clinical laboratories.
Awareness regarding early disease diagnosis with higher disease prevalence in North America will drive the market statistics
Get more details on this report - Request Free Sample PDF
North America market held over 35% revenue share in the overall market in 2021. Increasing prevalence of chronic diseases coupled with growing awareness regarding the early disease diagnosis will boost the regional market share. For instance, according to the report published by the Centers for Disease Control and Prevention (CDC) in 2020, more than 15% of adults in the U.S. were estimated to have CKD.
Additionally, as per the report of National Diabetes Statistics in 2020, 34.2 million i.e., 10.5% of the U.S. population had diabetes in the year. Thus, incidence of such conditions that require urine examination or urinalysis at frequent intervals will stimulate the market forecasts in the region. Moreover, extensive research and development activities performed by several research laboratories and presence of major market players in the region will stimulate the market share.
Continuous product launches and strategic partnerships among the market players will benefit the market size
The global market consists of numerous players. Few of the prominent market players operating in urinalysis industry are Sysmex Corporation, F. Hoffmann-La Roche Ltd, ACON Laboratories, Inc, Cardinal Health, Abbott, Bio-Rad Laboratories, Inc, ARKRAY, Inc, Erba Mannheim, Siemens Healthineers, Teco Diagnostics and 77 Elektronika Kft, among others. These market players are actively involved in product development and strategic collaborations to expand their business reach.
Some of the recent industry developments:
- In February 2021, 77 Elektronika Kft. announced the launch of LabStrip U mALB/CREA urine test strips. The product is intended for the rapid and semi-quantitative recognition of creatinine and albumin compounds in native urine. Such developments are expected to strengthen the company’s product offerings in the emerging markets.
- In January 2019, Bio-Rad Laboratories Inc., launched qUAntify, an advanced control for use in clinical labs performing urinalysis testing. It helps in monitoring the precision of laboratory urinalysis test procedures. This has assisted the company in strengthening its product portfolio in the market.
The urinalysis market report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2022 to 2028 for the following segments:
By Product
- Consumables
- Dipsticks
- Reagents
- Disposables
- Instruments
- Biochemical Urine Analyzer
- Automated Urine Sediment Analyzer
By Application
- Urinary Tract Infections [UTI]
- Kidney Disease
- Pregnancy
- Diabetes
- Others
By End-use
- Clinical Laboratories
- Hospitals
- Home Healthcare
- Others
The above information is provided for the following regions and countries:
By Region
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Spain
- Italy
- Others
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Others
- Latin America
- Brazil
- Mexico
- Argentina
- Others
- Middle East & Africa
- Saudi Arabia
- South Africa
- UAE
- Others
Frequently Asked Questions (FAQ) :